A Crohn&apos;s disease-associated IL2RA enhancer variant determines the balance of T cell immunity by regulating responsiveness to IL-2 signaling

Inflammatory Bowel Disease

Single-Cell Analyses of Colon and Blood Reveal Distinct Immune Cell Signatures of Ulcerative Colitis and Crohn's Disease

Gastroenterology.

Mitsialis V, Wall S, Liu P, Ordovas-Montanes J, Parmet T, Vukovic M, Spencer D, Field M, McCourt C, Toothaker J, Bousvaros A, BCH IBD Center., BWH Crohn’s and Colitis Center., Shalek AK, Kean L, Horwitz B, Goldsmith J, Tseng G, Snapper SB, Konnikova L

doi: 10.1053/j.gastro.2020.04.074.

Inflammatory Bowel Disease

T cell response after SARS-CoV-2 vaccination in immunocompromised patients with inflammatory bowel disease

J Crohns Colitis

Reuken PA, Andreas N, Grunert PC, Glöckner S, Kamradt T, Stallmach A

doi: 10.1093/ecco-jcc/jjab147

Inflammatory Bowel Disease

Metabonomics and the gut microbiome associated with primary response to anti-TNF therapy in Crohn's disease

J Crohns Colitis.

Ding NS, McDonald JAK, Perdones-Montero A, Rees DN, Adegbola SO, Misra R, Hendy P, Penez L, Marchesi JR, Holmes E, Sarafian MH, Hart AL

doi: 10.1093/ecco-jcc/jjaa039.

Inflammatory Bowel Disease

Mucosal Biomarker of Innate Immune Activation Predicts Response to Vedolizumab in Crohn's Disease

Inflamm Bowel Dis.

Osterman MT, Gordon IO, Davis EM, Ciorba M, Glover SC, Abraham B, Khan F, Guo X, Yee EU, Allard FD, Claggett B, Shen B, Liu JJ

doi: 10.1093/ibd/izz222.

Inflammatory Bowel Disease

Early Transmural Response Assessed Using Magnetic Resonance Imaging Could Predict Sustained Clinical Remission and Prevent Bowel Damage in Patients with Crohn's Disease Treated with Anti-Tumour Necrosis Factor Therapy

J Crohns Colitis.

Messadeg L, Hordonneau C, Bouguen G, Goutorbe F, Reimund JM, Goutte M, Boucher AL, Scanzi J, Reymond M, Allimant C, Dapoigny M, Pereira B, Bommelaer G, Buisson A

doi: 10.1093/ecco-jcc/jjaa098.

Inflammatory Bowel Disease

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study

Lancet Gastroenterol Hepatol.

Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R, Perry MH, Bouri S, Chanchlani N, Heerasing NM, Hendy P, Lin S, Gaya DR, Cummings JRF, Selinger CP, Lees CW, Hart AL, Parkes M, Sebastian S, Mansfield JC, Irving PM, Lindsay J, Russell RK, McDonald TJ, McGovern D, Goodhand JR, Ahmad T; UK Inflammatory Bowel Disease Pharmacogenetics Study Group

doi: 10.1016/S2468-1253(19)30012-3.

Inflammatory Bowel Disease

Shorter Disease Duration is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease but Not Ulcerative Colitis

Clin Gastroenterol Hepatol.

Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland B, Singh S, Hirten R, Shmidt E, Kesar V, Lasch K, Luo M, Bohm M, Varma S, Fischer M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Shen B, Sandborn WJ, Kane S, Loftus EV Jr, Sands BE, Colombel JF, Dulai PS, Ungaro R

doi: 10.1016/j.cgh.2018.12.040.

Inflammatory Bowel Disease

Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study

Lancet Gastroenterol Hepatol.

Feagan BG, Sandborn WJ, Danese S, Wolf DC, Liu WJ, Hua SY, Minton N, Olson A, D'Haens G

doi: 10.1016/S2468-1253(20)30188-6.

Inflammatory Bowel Disease

Persistent mesorectal inflammatory activity is associated with complications after proctectomy in Crohn's Disease

J Crohns Colitis.

de Groof EJ, van der Meer JHM, Tanis PJ, de Bruyn JR, van Ruler O, D'Haens GRAM, van den Brink GR, Bemelman WA, Wildenberg ME, Buskens CJ

doi: 10.1093/ecco-jcc/jjy131.

Related content

Single-Cell Analyses of Colon and Blood Reveal Distinct Immune Cell Signatures of Ulcerative Colitis and Crohn's Disease

T cell response after SARS-CoV-2 vaccination in immunocompromised patients with inflammatory bowel disease

Metabonomics and the gut microbiome associated with primary response to anti-TNF therapy in Crohn's disease

Mucosal Biomarker of Innate Immune Activation Predicts Response to Vedolizumab in Crohn's Disease

Early Transmural Response Assessed Using Magnetic Resonance Imaging Could Predict Sustained Clinical Remission and Prevent Bowel Damage in Patients with Crohn's Disease Treated with Anti-Tumour Necrosis Factor Therapy

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study

Shorter Disease Duration is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease but Not Ulcerative Colitis

Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study

Persistent mesorectal inflammatory activity is associated with complications after proctectomy in Crohn's Disease